- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
75 result(s) found for: Enzyme immunoassay.
Displaying page 1 of 4.
EudraCT Number: 2011-004435-31 | Sponsor Protocol Number: MVC116278 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc. | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016480-11 | Sponsor Protocol Number: 2009HD/01 | Start Date*: 2009-12-28 | |||||||||||
Sponsor Name:P Pierre Dellamonica | |||||||||||||
Full Title: “No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected b... | |||||||||||||
Medical condition: HIV naïve patients, CCR5 tropism, with CD4 > 200/mm3 and HIV RNA < 100 000 copy/ml. | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006009-18 | Sponsor Protocol Number: TMC278-TiDP15-C221 | Start Date*: 2009-04-17 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy. | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008190-58 | Sponsor Protocol Number: TMC310911-TiDP21-C201 | Start Date*: 2009-04-03 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003484-22 | Sponsor Protocol Number: PNC+AHEP | Start Date*: 2012-09-11 |
Sponsor Name:Helsinki University Central Hospital | ||
Full Title: Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly | ||
Medical condition: 18 years old or older volunteers with general good health | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-004617-34 | Sponsor Protocol Number: NV20911 | Start Date*: 2008-01-15 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old | |||||||||||||
Medical condition: HIV-1 Infection/AIDS | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004306-50 | Sponsor Protocol Number: A4001050 | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) IT (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005063-16 | Sponsor Protocol Number: IEO370 | Start Date*: 2017-07-17 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: A randomized presurgical study with different schedules of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer | |||||||||||||
Medical condition: Postmenopausal ER positive breast cancer, waiting for surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002183-26 | Sponsor Protocol Number: TMC125-C126 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children. | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000748-14 | Sponsor Protocol Number: M06-802 | Start Date*: 2006-08-14 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... | |||||||||||||
Medical condition: Antiretroviral experienced, HIV-1 Infection. Adequate ICD classification code not available. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000712-27 | Sponsor Protocol Number: TMC125-C229 | Start Date*: 2005-07-15 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals Limited | |||||||||||||
Full Title: An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008655-42 | Sponsor Protocol Number: TMC125VIR2038 | Start Date*: 2009-03-31 | |||||||||||
Sponsor Name:Janssen Cilag International | |||||||||||||
Full Title: A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combinat... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) HU (Completed) AT (Completed) DE (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007086-21 | Sponsor Protocol Number: TMC125-TiDP35-C213 | Start Date*: 2009-01-23 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents. | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) FR (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004225-26 | Sponsor Protocol Number: GS-US-183-0145 | Start Date*: 2008-08-13 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Backgrou... | |||||||||||||
Medical condition: Human Innunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003835-28 | Sponsor Protocol Number: APHP210089 | Start Date*: 2022-02-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS | |||||||||||||
Full Title: Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ” VANCALLO | |||||||||||||
Medical condition: Patients hospitalized for an allogeneic hematopoietic stem cell transplant | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013657-14 | Sponsor Protocol Number: AI438006 | Start Date*: 2009-11-10 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003917-29 | Sponsor Protocol Number: GS-US-183-0152 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents | |||||||||||||
Medical condition: Human Innunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003995-21 | Sponsor Protocol Number: ERRADVIH-01 | Start Date*: 2007-12-03 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | |||||||||||||
Full Title: Estudio piloto del efecto de un antagonista de co-receptores CCR5 sobre la latencia y el reservorio del VIH-1 en pacientes que reciben tratamiento antirretroviral de gran actividad | |||||||||||||
Medical condition: VIH | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003354-28 | Sponsor Protocol Number: GS-UK-177-0109 | Start Date*: 2008-02-19 | |||||||||||
Sponsor Name:Gilead Sciences Limited | |||||||||||||
Full Title: A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Onc... | |||||||||||||
Medical condition: Adult, HIV-1 infected, tenofovir DF- and emtricitabine-naive subjects on a stable HAART regimen of Kivexa (abacavir/lamivudine) and efavirenz, with raised total fasting cholesterol | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002045-23 | Sponsor Protocol Number: GS-US-180-0104 | Start Date*: 2008-07-18 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects. | |||||||||||||
Medical condition: Antiretroviral treatment–naive subjects chronically infected with HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
